title: Prognostic role of metastasis tumor antigen 1 in patients with ovarian cancer: a clinical study.
abstract: In this study, we investigated the prognostic value of metastasis tumor antigen 1 expression in 81 untreated patients with ovarian cancer. The expression of metastasis tumor antigen 1 was evaluated by immunohistochemistry, and staining was analyzed in relation to clinicopathologic variables, disease-free survival, and overall survival. High expression of metastasis tumor antigen 1 was found to be associated with advanced stage (I/II versus III/IV, P = .02) and with worse response to first-line treatment (P = .03). Cases with high metastasis tumor antigen 1 expression showed a lower disease-free survival compared with cases with low expression (P = .02). In multivariate analysis of disease-free survival, metastasis tumor antigen 1 overexpression retained an independent negative prognostic role (P = .04), when considered together with histotype, stage of disease, residual tumor at surgery, and chemosensitivity. The evaluation of the prognostic relevance of metastasis tumor antigen 1 in late-stage disease showed that overexpression was a prognostic factor for poor disease-free survival and overall survival in this subset of patients, in both univariate and multivariate models. These findings indicate that metastasis tumor antigen 1 overexpression can be used as a predictor of clinical outcome in patients with ovarian cancer and therefore may represent a new prognostic marker.
authors.affiliation: Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Largo A. Gemelli, 8-00168, Rome, Italy.
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Prisco
authors.forename: Gian Franco
authors.initials: GF
authors.lastname: Zannoni
authors.forename: Ilaria
authors.initials: I
authors.lastname: De Stefano
authors.forename: Valerio Gaetano
authors.initials: VG
authors.lastname: Vellone
authors.forename: Lucia
authors.initials: L
authors.lastname: Tortorella
authors.forename: Anna
authors.initials: A
authors.lastname: Fagotti
authors.forename: Liliana
authors.initials: L
authors.lastname: Mereu
authors.forename: Giovanni
authors.initials: G
authors.lastname: Scambia
authors.forename: Daniela
authors.initials: D
authors.lastname: Gallo
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality / Q000556:secondary*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D005260:Female; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D012097:Repressor Proteins / Q000378:metabolism*; D016019:Survival Analysis; D015996:Survival Rate; D013624:Taiwan / Q000453:epidemiology; D015534:Trans-Activators
chemical_list: D014408:Biomarkers, Tumor; C089320:MTA1 protein, human; D012097:Repressor Proteins; D015534:Trans-Activators; D006655:Histone Deacetylases